800-372-8304
  • Medicare Fraud 101 Blog
  • Qui Tam 101 Blog
Nolan Auerbach & White
  • Main Site

Guess What Else is NOT a Top Priority of the FDA?

Posted July 12, 2006 in LegalClinical Trials, Drug Safety, FDA, U.S. Food and Drug Administration

Answer: Monitoring postmarketing study commitments.

The FDA lacks an effective system for monitoring postmarketing study commitments.  See the latest OIG Report, dated June 2006.

Post navigation

← The Decline In FDA Enforcement Activity Drug scandal allegedly reveals pattern of scientific fraud at the FDA →
Serious Cases. Serious Attention.
Contact Form - Your First Step
Proudly Serving The Nation

Fort Lauderdale

435 North Andrews Avenue
Suite 401
Fort Lauderdale, Florida 33301
(800) 372-8304

San Francisco

110 Pacific Avenue
Suite 162
San Francisco, California 94111
(800) 372-8304

Novato

750 Grant Avenue
Suite 250
Novato, California 94945
(800) 372-8304

Philadelphia

One Penn Center
1617 John F Kennedy
Boulevard, Suite 1025
Philadelphia, Pennsylvania 19103-1844
(800) 372-8304

© 2023 Nolan Auerbach & White, P.A. All Rights Reserved.

Web Design by Round Robin Studios

Omnicare In Trouble

Omnicare is the nation’s largest supplier of prescription drugs for nursing homes serving approximately 1.4 patents or more than half the market.  However, the company appears to be under investigation for its Medicaid billing practices in three states: Massachusetts, Ohio and Michigan Omnicare’s top executive in Michigan has been indicted on racketeering and Medicaid fraud charges. A spokesperson for the Michigan Attorney General’s Office says the investigation is far from finished. In January 2006, Omnicare disclosed that the U.S. Attorney’s Office in Massachusettts had subpoenaed documents that focused on its relationships with drug manufacturers and distributors.  In addition Johnson & Johnson in 2005 disclosed that its company received a subpoena in September 2005 from the U.S. Attorney’s Office in Massachusetts “seeking documents related to sales and marketing of eight drugs to Omnicare, Inc.”

For more information click here.

[contact-form-7 id="1603" title="Contact Form - Modal"]